Ammar Adam

1.3k total citations
17 papers, 371 citations indexed

About

Ammar Adam is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Ammar Adam has authored 17 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Pathology and Forensic Medicine and 4 papers in Immunology. Recurrent topics in Ammar Adam's work include Cancer Mechanisms and Therapy (5 papers), Phagocytosis and Immune Regulation (4 papers) and Liver physiology and pathology (4 papers). Ammar Adam is often cited by papers focused on Cancer Mechanisms and Therapy (5 papers), Phagocytosis and Immune Regulation (4 papers) and Liver physiology and pathology (4 papers). Ammar Adam collaborates with scholars based in United States, United Kingdom and Austria. Ammar Adam's co-authors include Bhuvanesh Dave, Judy C. Chang, Chad J. Creighton, T. Kris Eckols, Melissa D. Landis, Michael T. Lewis, Uddalak Bharadwaj, Mikhail Kolosov, Moses M. Kasembeli and Michael A. Mancini and has published in prestigious journals such as Blood, Cancer Research and Oncogene.

In The Last Decade

Ammar Adam

15 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ammar Adam United States 9 194 101 80 72 63 17 371
Dongwei Jia China 15 344 1.8× 124 1.2× 104 1.3× 40 0.6× 28 0.4× 23 584
Graziella Malaponte Italy 9 241 1.2× 125 1.2× 69 0.9× 16 0.2× 49 0.8× 10 481
Naveenkumar Perumal United States 12 256 1.3× 97 1.0× 65 0.8× 30 0.4× 47 0.7× 17 454
Shi-Bing Su China 10 249 1.3× 82 0.8× 30 0.4× 87 1.2× 47 0.7× 10 428
Weijie Qiang China 8 169 0.9× 69 0.7× 36 0.5× 35 0.5× 95 1.5× 14 327
Ahmed A. Ashour Egypt 10 296 1.5× 72 0.7× 34 0.4× 21 0.3× 43 0.7× 18 433
Eui‐Kyu Noh South Korea 13 213 1.1× 80 0.8× 96 1.2× 21 0.3× 30 0.5× 25 503
Haiyan Ma China 11 143 0.7× 105 1.0× 50 0.6× 24 0.3× 36 0.6× 11 304
Xiaodan Sun China 14 304 1.6× 113 1.1× 62 0.8× 36 0.5× 62 1.0× 39 556

Countries citing papers authored by Ammar Adam

Since Specialization
Citations

This map shows the geographic impact of Ammar Adam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ammar Adam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ammar Adam more than expected).

Fields of papers citing papers by Ammar Adam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ammar Adam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ammar Adam. The network helps show where Ammar Adam may publish in the future.

Co-authorship network of co-authors of Ammar Adam

This figure shows the co-authorship network connecting the top 25 collaborators of Ammar Adam. A scholar is included among the top collaborators of Ammar Adam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ammar Adam. Ammar Adam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Sandoval, Gabriel J., Richard C. Centore, GiNell Elliott, et al.. (2023). Abstract A056: Treatment with dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 ablates tumor-associated androgen response elements (AREs) in prostate cancer. Molecular Cancer Therapeutics. 22(12_Supplement). A056–A056.
2.
Collins, Mike, Gabriel J. Sandoval, Ammar Adam, et al.. (2023). Abstract 2122: The dual BRM/BRG1 (SMARCA2/4) inhibitor FHD-286 induces differentiation in preclinical models of AML. Cancer Research. 83(7_Supplement). 2122–2122. 2 indexed citations
3.
Wilson, Molly M., Ammar Adam, Oliver R. Mikse, et al.. (2023). Abstract A064: Establishing the cellular and molecular impacts of the dual BRM/BRG1 inhibitor FHD-286 on pre-clinical models of non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 22(12_Supplement). A064–A064.
4.
Ichikawa, Kana, Ammar Adam, Hsin‐Jung Wu, et al.. (2022). 888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models. Regular and Young Investigator Award Abstracts. A925–A925. 2 indexed citations
5.
Adam, Ammar, Li Zhang, Rachel W O’Connor, et al.. (2020). The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a. Journal for ImmunoTherapy of Cancer. 8(1). e000413–e000413. 42 indexed citations
6.
7.
Hird, Alexander W., J. Paul Secrist, Ammar Adam, et al.. (2017). Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers. Cancer Research. 77(13_Supplement). DDT01–2. 15 indexed citations
8.
Holland, Pamela M., Emmanuel Normant, Ammar Adam, et al.. (2016). CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies. Blood. 128(22). 1843–1843. 10 indexed citations
9.
Henry, Ryan E., Evan Barry, Lillian Castriotta, et al.. (2016). Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget. 7(36). 57651–57670. 27 indexed citations
10.
Schuller, Alwin G., Evan Barry, Rhys D.O. Jones, et al.. (2015). The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models. Clinical Cancer Research. 21(12). 2811–2819. 57 indexed citations
11.
Hennessy, Edward J., Vibha Oza, Ammar Adam, et al.. (2015). Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity. Journal of Medicinal Chemistry. 58(17). 7057–7075. 19 indexed citations
12.
Bharadwaj, Uddalak, T. Kris Eckols, Mikhail Kolosov, et al.. (2014). Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 34(11). 1341–1353. 137 indexed citations
13.
Belmonte, Matthew A., et al.. (2014). Evaluation of Mcl-1 Inhibitors in Preclinical Models of Multiple Myeloma. Blood. 124(21). 3428–3428. 2 indexed citations
14.
Adam, Ammar, Kate F. Byth, Alwin G. Schuller, et al.. (2014). A Dual Bcl-2/xL Inhibitor Induces Tumor Cell Apoptosis in a Hematopoietic Xenograft Model. Blood. 124(21). 5304–5304. 4 indexed citations
15.
D’Cruz, Celina M., Melanie M. Frigault, Ammar Adam, et al.. (2014). Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC. Cancer Research. 74(19_Supplement). 3114–3114. 6 indexed citations
16.
Kenessey, István, Zachary Kramer, Judit Berta, et al.. (2010). Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma. Current Cancer Drug Targets. 10(3). 332–342. 26 indexed citations
17.
Gärtner, H.-V., Tsuyoshi Watanabe, Ammar Adam, et al.. (1977). Correlations Between Morphologic and Clinical Features in Idiopathic Perimembranous Glomerulonephritis. Current topics in pathology. 1–29. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dongwei Jia Breakdown of academic impact, for papers by Graziella Malaponte Breakdown of academic impact, for papers by Naveenkumar Perumal Breakdown of academic impact, for papers by Shi-Bing Su Breakdown of academic impact, for papers by Weijie Qiang Breakdown of academic impact, for papers by Ahmed A. Ashour Breakdown of academic impact, for papers by Eui‐Kyu Noh Breakdown of academic impact, for papers by Haiyan Ma Breakdown of academic impact, for papers by Xiaodan Sun
Rankless by CCL
2026